应对抗CD47抗体药物干扰输血相容性检测的中国专家共识*

doi:10.3969/j.issn.1671-2587.2025.01.002

临床输血与检验 ›› 2025, Vol. 27 ›› Issue (1): 13-20.DOI: 10.3969/j.issn.1671-2587.2025.01.002

应对抗CD47抗体药物干扰输血相容性检测的中国专家共识^*

中国输血协会临床输血学专业委员会

收稿日期:2024-10-19 发布日期:2025-02-25
通讯作者: 王学锋,主要从事出血性疾病及血栓病诊治相关研究,（E-mail）wxf63@shsmu.edu.cn;谢珏,主要从事输血医学研究,（E-mail）zyyyxj2011@163.com;向东,主要从事免疫血液学研究,（E-mail）xiangdong@sbc.org.cn;胡丽华,主要从事输血医学基础与临床研究,（E-mail）xhhulh@126.com。
作者简介:蔡晓红,主要从事血液成分输注的临床和基础研究,（E-mail）cxh8407@sjtu.edu.cn;胡兴斌,主要从事输血医学研究,（E-mail）hulab2023@163.com;娄璨,主要从事红细胞血型与输血免疫方面研究,（E-mail）loucan971217@163.com。
基金资助:
*本课题受国家自然科学基金(No. 82070194、No. 82370229)资助

Expert Consensus on Interference of anti-CD47 Antibody with Compatibility Test in Chinese

Clinical Transfusion Medicine Professional Committee of the Chinese Society of Blood Transfusion

Received:2024-10-19 Published:2025-02-25

摘要/Abstract

摘要： 随着免疫检查点的不断发现以及相应抗体药物的研发革新,抗体药物在肿瘤中的应用越来越广泛。但某些免疫检查点治疗的靶标分子不仅在肿瘤细胞中表达,也在正常的红细胞中表达,故这类药物的应用可能会对输血相容性检测造成干扰,导致配血困难和输血延迟。CD47即整合素相关蛋白（integrin associated protein,IAP）,是一种表达在多种细胞表面的跨膜蛋白,是“别吃我”信号的关键分子;; 尽管近年来一些抗CD47抗体药物的临床试验遇到挑战,这一领域的研发活动依然活跃,显示出其在肿瘤治疗中的潜力。本共识旨在总结抗CD47抗体药物对输血相容性检测的干扰,并推荐使用乏IgG4抗人球蛋白试剂和抗独特型抗体等方法去除干扰,为临床安全输血提供保障。

关键词: CD47, 抗CD47抗体药物, 输血前相容性检测, 干扰, 抗独特型抗体, 乏IgG4抗人球蛋白试剂

Abstract: With the continuous discovery of immune checkpoints and development of antibody drugs, the application of antibody drugs in tumors has become more and more widespread. However, some immune checkpoints are expressed not only in tumor cells but also in normal erythrocytes, so the application of such drugs may interfere with the transfusion compatibility test, leading to difficulties in blood matching and delays in transfusion. CD47, also known as Integrin Associated Protein (IAP), is a transmembrane protein expressed on the surface of a variety of cells and key signaling molecule of "Don't eat me". Although some clinical trials of anti-CD47 antibody have encountered challenges in recent years, research and development activity in this area remains active, showing its potential in cancer treatment. The purpose of this consensus is to summarize the interference of CD47 antibody on transfusion compatibility test and recommend methods such as using lack IgG4 anti-globulin and anti-idiotype antibody to remove the interference and provide a guarantee for safe clinical blood transfusion.

Key words: CD47, CD47 antibody, compatibility test, Interference, Anti-idiotype antibody, IgG4-deficient anti-human globulin reagent

中图分类号:

R457R446.6

中国输血协会临床输血学专业委员会. 应对抗CD47抗体药物干扰输血相容性检测的中国专家共识^*[J]. 临床输血与检验, 2025, 27(1): 13-20.

Clinical Transfusion Medicine Professional Committee of the Chinese Society of Blood Transfusion. Expert Consensus on Interference of anti-CD47 Antibody with Compatibility Test in Chinese[J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2025, 27(1): 13-20.

参考文献

[1] LI B,CHAN H L,CHEN P P.Immune checkpoint inhibitors:basics and challenges[J].Curr Med Chem,2019,26(17):3009-3025.
[2] LOGTENBERG M E W,SCHEEREN F A,SCHUMACHE R T N.The CD47-SIRPα immune checkpoint[J].Immunity,2020,52(5):742-752.
[3] WANG R J,ZHANG C,CAO Y T,et al.Blockade of dual immune checkpoint inhibitory signals with a CD47/PD-L1 bispecific antibody for cancer treatment[J].Theranostics,2023,13(1):148-160.
[4] VELLIQUETTE R W,AESCHLIMANN J,KIRKEGAARD J,et al.Monoclonal anti-CD47 interference in red cell and platelet testing[J].Transfusion,2019,59(2):730-737.
[5] OLDENBORG P A,ZHELEZNYAK A,FANG Y F,et al.Role of CD47 as a marker of self on red blood cells[J].Science,2000,288(5473):2051-2054.
[6] CHAO M P,ALIZADEH A A,TANG C,et al.Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma[J].Cell,2010,142(5):699-713.
[7] KIM D,WANG J,WILLINGHAM S B,et al.Anti-CD47 antibodies promote phagocytosis and inhibit the growth of human myeloma cells[J].LeukeMi^a,2012,26(12):2538-2545.
[8] CHAO M P,ALIZADEH A A,TANG C,et al.Therapeut ic antibody targeting of CD47 eliminates human acute lymphoblastic leukeMi^a[J].Cancer Res,2011,71(4):1374-1384.
[9] PETROVA P S,VILLER N N,WONG M,et al.TTI-621(SIRPαFc):a CD47-blocking innate immune checkpoint inhibitor with broad antitumor activity and minimal erythrocyte binding[J].Clin Cancer Res,2017,23(4):1068-1079.
[10] ADVANI R,FLINN I,POPPLEWELL L,et al.CD47 blockade by Hu5F9-G4 and rituximab in non-Hodgkin’s lymphoma[J].N Engl J Med,2018,379(18):1711-1721.
[11] 陈洁,胡兴斌,陈要臻,等.单克隆抗-CD47干扰输血前检测:国内外临床试验案例分析[J].中国输血杂志,2021,34(11):1215-1218.
[12] BERLIN J,HARB W,ADJEI A,et al.385 A first-in-human study of lemzoparlimab,a differentiated anti-CD47 antibody,in subjects with relapsed/refractory malignancy: initial monotherapy results[J].Journal for ImmunoTherapy of Cancer,2020,8: A410-A410.
[13] WANG H F,ZHANG Q K,TENG Q L,et al.A Phase 1b Study Evaluating the Safety and Efficacy of AK117(anti-CD47 monoclonal antibody)in Combination with Azacitidine in Patients with Treatment-Naïve Acute Myeloid LeukeMi^a[J].Blood,2023,142:4280.
[14] Mi^aO M,TENG Q L,WU D P,et al.AK117(anti-CD47 monoclonal antibody)in combination with azacitidine for newly Di^agnosed higher risk myelodysplastic syndrome(HR-MDS):AK117-103 phase 1b results[J].Blood,2023,142:1865.
[15] YU J F,LI S,CHEN D Z,et al.SIRPα-Fc fusion protein IMM01 exhibits dual anti-tumor activities by targeting CD47/SIRPα signal pathway via blocking the “don’t eat me” signal and activating the “eat me” signal[J].J Hematol Oncol,2022,15(1):167.
[16] YANG W,GAO S J,YAN X J,et al.Latest results of a phase 2 study of IMM01 combined with azacitidine(AZA)as the first-line treatment in adults with higher risk myelodysplastic syndromes(MDS)[J].J Clin Oncol,2024,42(16_suppl):6510.
[17] SONG Z B,TONG X,ZHANG Y,et al.IMM01 plus tislelizumab in patients with advanced solid tumors and lymphoma:an open-label,multicenter,phase 1b/2 dose escalation and expansion study(IMM01-04)[J].J Clin Oncol,2023,41(16_suppl):2600.
[18] YU J F,LI S,CHEN D Z,et al.IMM0306,a fusion protein of CD20 MAb with the CD47 binding domain of SIRPα,exerts excellent cancer killing efficacy by activating both macrophages and NK cells via blockade of CD47-SIRPα interaction and FcɣR engagement by simultaneously binding to CD47 and CD20 of B cells[J].LeukeMi^a,2023,37(3):695-698.
[19] CHAUCHET X,CONS L,CHATEL L,et al.CD47xCD19 bispecific antibody triggers recruitment and activation of innate immune effector cells in a B-cell lymphoma xenograft model[J].Exp Hematol Oncol,2022,11(1):26.
[20] UPTON R,BANUELOS A,FENG D D,et al.Combining CD47 blockade with trastuzumab eliminates HER2-positive breast cancer cells and overcomes trastuzumab tolerance[J].Proc Natl Acad Sci U S A,2021,118(29):e2026849118.
[21] QU T L,ZHONG T T,PANG X H,et al.Ligufalimab,a novel anti-CD47 antibody with no hemagglutination demonstrates both monotherapy and combo antitumor activity[J].J Immunother Cancer,2022,10(11):e005517.
[22] LIU Z R,CHEN H Y,TA N,et al.Anti-CD47 antibody enhances the efficacy of chemotherapy in patients with gastric cancer liver metastasis[J].J Cancer,2023,14(3):350-359.
[23] DAHL K N,WESTHOFF C M,DISCHER D E.Fractional attachment of CD47(IAP)to the erythrocyte cytoskeleton and visual colocalization with Rh protein complexes[J].Blood,2003,101(3):1194-1199.
[24] REINHOLD M I,LINDBERG F P,PLAS D,et al.In vivo expression of alternatively spliced forms of integrin-associated protein(CD47)[J].J Cell Sci,1995,108( Pt 11):3419-3425.
[25] BRIERLEY C K,STAVES J,ROBERTS C,et al.The effects of monoclonal anti-CD47 on RBCs,compatibility testing,and transfusion requirements in refractory acute myeloid leukeMi^a[J].Transfusion,2019,59(7):2248-2254.
[26] 吕依扬,孔文兵,陈晓钢,等.抗-CD47单抗对输血相容性检测的干扰及处理[J].中国输血杂志,2023,36(3):238-241.
[27] 糜坚青,蔡晓红,王少元,等.CD38单克隆抗体对输血相容性检测干扰及其应对方案的专家共识[J].中国输血杂志,2021,34(4):327-334.
[28] JIANG Z X,SUN H,YU J F,et al.Targeting CD47 for cancer immunotherapy[J].J Hematol Oncol,2021,14(1):180.
[29] MURPHY M F,RAJBHANDARY S,CARAYIANNIS S,et al.How do transfusion services manage patients taking therapies such as anti-CD38 and anti-CD47 known to interfere with red blood cell compatibility testing?[J].Transfusion,2024,64(7):1217-1222.
[30] 马春娅,李小飞,于洋,等.红细胞意外抗体筛查与鉴定抗原谱构成中国专家共识[J].临床输血与检验,2024,26(2):156-163.
[31] 中华预防医学会血液安全专业委员会红细胞血型意外抗体筛查专家共识编写组.红细胞血型意外抗体筛查专家共识[J].中国输血杂志,2024,37(4):369-376.
[32] 李小飞,马春娅,蔡晓红,等.红细胞血型抗原拓展匹配适用范围中国专家共识[J].临床输血与检验,2024,26(3):289-298.
[33] WESTHOFF C M.Blood group genotyping[J].Blood,2019,133(17):1814-1820.
[34] 莫春妍,岑雨贞,王贞,等.抗-CD47单克隆抗体对输血前检测试验的干扰及处理措施——附1例报告[J].中国输血杂志,2021,34(3):290-292.
[35] 李鹏,房阔,张警丹,等.抗独特型抗体在CD47单抗治疗患者抗体筛查和配血中的应用[J].中国输血杂志,2024,37(4):392-398.
[36] KIM T Y,YOON M S,HUSTINX H,et al.Assessing and mitigating the interference of ALX148,a novel CD47 blocking agent,in pretransfusion compatibility testing[J].Transfusion,2020,60(10):2399-2407.
[37] WEI H,CUI Y,REN D X,et al.Pretreatment with Daudi cells eliminates anti-CD47 monoclonal antibody interference in immunohematology testing[J].Trasfusione Del Sangue,2024,22(1):20-29.
[38] WANG F,WANG W T,WU X S,et al.Depletion of anti-CD47mAb in plasma by genetically modified cells for pre-transfusion testing[J].Genes Dis,2024,11(5):101104.
[39] 中国医师协会输血科医师分会,中华医学会临床输血学分会.特殊情况紧急抢救输血推荐方案[J].中国输血杂志,2014,27(1):1-3.

应对抗CD47抗体药物干扰输血相容性检测的中国专家共识^*

Expert Consensus on Interference of anti-CD47 Antibody with Compatibility Test in Chinese

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 5

编辑推荐

Metrics

本文评价

关于本刊

作者中心

在线期刊

访问统计

联系我们

[1]	王斐, 陈要臻, 胡兴斌. 抗CD-38和抗CD-47单抗药物对输血相容性检测的干扰与应对策略研究进展^*[J]. 临床输血与检验, 2023, 25(4): 559-563.
[2]	刘静, 李龙, 马喜迎. γ-干扰素释放试验联合FadD9重组蛋白对重症肺结核患者的诊断及死亡预后的预测价值[J]. 临床输血与检验, 2022, 24(4): 488-496.
[3]	王海妮, 陈安青. 血清IFN-γ、IL-2、EGF预测鼻咽癌患者放疗敏感性和预后的相关性分析[J]. 临床输血与检验, 2020, 22(3): 300-304.
[4]	尹美玲, 李明, 崔花芹, 单武林, 阚劲松. 结核γ干扰素释放试验在结核病诊断中的价值^*[J]. 临床输血与检验, 2019, 21(6): 589-591.
[5]	吴学忠, 胡晓玉, 吴君胜, 郭晓婕. TPPA阳性献血者IL-4、IL-10和IFN-γ水平检测分析[J]. 临床输血与检验, 2019, 21(5): 488-490.